Research Reports
- 11/14/2023
3Q23 Reported As Three Trials Make Progress
- 11/1/2023
Phase 2a Influenza Trial Receives Authorization To Begin
- 10/2/2023
CDI-988 Begins Phase 1a/b Clinical Trial
- 8/15/2023
2Q23 Reported With New Clinical Trials Ready To Begin
- 5/15/2023
Products Are Advancing Toward Clinical Milestones
- 3/30/2023
FY2022 Reported With New Clinical Trials On Track
- 12/20/2022
Safety and Tolerability Data From Influenza Study Announced
- 11/16/2022
3Q22 Reported – First Influenza Vaccine Data To Be Presented
- 9/12/2022
Influenza Program Update
- 8/16/2022
2Q Reported With Influenza and COVID-19 Product Updates
- 5/12/2022
Influenza Trial Continues With New Clinical Trials Planned For COVID-19
- 4/13/2022
First Results From Influenza Program Announced
